This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Various				
Sepsis; shock/trauma	Cold-inducible RNA-binding protein (CIRP)	<i>In vitro</i> and rodent studies suggest decreasing CIRP levels could help treat hemorrhagic shock and sepsis. In hemorrhaged human patients and in a rat model of hemorrhagic shock, serum CIRP levels were greater than those in healthy controls. In mouse and rat models of hemorrhagic shock and sepsis, <i>Cirp</i> knockout or a Cirp-neutralizing antibody decreased the inflammatory response and mortality compared with no knockout or an IgG control. Next steps include testing therapeutic peptide fragments of human CIRP that interfere with its function in animal models of sepsis.	Patent applications filed; TheraSource LLC has an option to license the IP; available for licensing from The Feinstein Institute for Medical Research and TheraSource	Qiang, X. <i>et al. Nat. Med.</i> ; published online Oct. 6, 2013; doi:10.1038/nm.3368 Contact: Ping Wang, The Feinstein Institute for Medical Research, Manhasset, N.Y. e-mail: pwang@nshs.edu
<i>SciBX</i> 6(43); doi:10.1038/scibx.2013.1235 Published online Nov. 7, 2013				